论文部分内容阅读
[目的]初探盐酸吉西他滨(健择)治疗晚期和复发性妇癌的效果和毒性。[方法]2000年12月～2001年8月7例局部晚期和复发性妇癌接受健择治疗 ,其中2例卵巢癌采用GT方案 :健择800mg/m2静注30分钟 ,d1 ,8,泰素帝40mg/m2静点 ,d1 ,8,28天重复 ;3例宫颈癌 ,1例阴道癌及1例子宫内膜癌均予以GP方案健择800mg/m2静注30分钟 ,d1 ,8,顺铂20mg/m2静注 ,d2～4,28天重复。7例患者共接受13个疗程。[结果]7例均可评价疗效和毒性。1例宫颈癌ⅠB2期新辅助化疗获得部分缓解 ,6例病情进展(PD) ,其中肺转移4例中2例肿瘤缩小或肺包裹性积液减少(不及50 %) ,但伴有其他病灶增大或出现新转移灶。主要不良反应是血液学毒性 ,白细胞下降Ⅱ度占46.2%疗程 ,贫血Ⅲ度占15.4%疗程 ,血小板减少Ⅲ～Ⅳ度占38.4 %疗程。[结论]健择与顺铂或泰素帝联合在宫颈癌新辅助化疗中提高放疗增敏性 ,在多脏器、多部位转移的复发妇癌患者的拯救性治疗中疗效差,毒性较大但能耐受
[Objective] To explore the effect and toxicity of gemcitabine hydrochloride (Jianzheng) on advanced and recurrent women with cancer. [Methods] From December 2000 to August 2001, 7 cases of locally advanced and recurrent esophageal cancer were treated with gemcitabine. Two cases of ovarian cancer were treated with GT regimen: Gemcitabine 800 mg / m2 for 30 minutes, d1, 8, Su Huang 40mg / m2 static point, d1, 8,28 days repeated; 3 cases of cervical cancer, 1 case of vaginal cancer and 1 case of endometrial cancer were given GP regimen 800mg / m2 intravenously for 30 minutes, d1, 8, Cisplatin 20mg / m2 intravenous, d2 ~ 4,28 days repeat. Seven patients received a total of 13 courses. [Results] All the 7 cases could evaluate the curative effect and toxicity. 1 case of cervical cancer neoadjuvant chemotherapy achieved partial remission in 6 cases, 6 cases of disease progression (PD), of which 4 cases of lung metastases, 2 cases of tumor shrinkage or reduced lung encapsulation fluid (less than 50%), but with other lesions increased Large or appear new metastases. The main adverse reactions were hematological toxicity, leukopenia Ⅱ accounted for 46.2% of courses, anemia Ⅲ accounted for 15.4% of courses, thrombocytopenia Ⅲ ~ Ⅳ accounted for 38.4% of the course. [Conclusion] Combination of gemcitabine and cisplatin or docetaxel can improve radiosensitivity in neoadjuvant chemotherapy of cervical cancer and has poor curative effect and high toxicity in the salvage treatment of recurrent esophageal cancer patients with multi-organ and multi-site metastasis But can tolerate